Anzeige
Meldung des Tages: Bohrtreffer, Infrastruktur, Finanzierung: Beginnt hier der Weg zur Produktion?

ADC Therapeutics News

Aktie
WKN:  A2PSR8 ISIN:  CH0499880968 US-Symbol:  ADCT Branche:  Biotechnologie Land:  Schweiz
4,43 $
+0,06 $
+1,37%
3,7590 € 21:01:08 Uhr
Depot/Watchlist
Marktkapitalisierung *
295,73 Mio. €
Streubesitz
27,64%
KGV
-1,33
Index-Zuordnung
-

ADC Therapeutics News

01.04.26 - PR Newswire
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics Announces New Employee Inducement Grant PR Newswire
10.03.26 - PR Newswire
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update PR Newswire
03.03.26 - PR Newswire
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026 PR Newswire
02.03.26 - PR Newswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire
24.02.26 - PR Newswire
ADC Therapeutics to Participate in March Investor Conferences
ADC Therapeutics to Participate in March Investor Conferences PR Newswire
23.02.26 - PR Newswire
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement PR Newswire
02.02.26 - PR Newswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire
30.01.26 - PR Newswire
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
$170B Patent Cliff Ignites Biotech Deal Wave: Late-​Stage Platforms Command Premium PR Newswire
22.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire
15.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire
08.01.26 - PR Newswire
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates PR Newswire
08.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire
08.01.26 - PR Newswire
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
02.01.26 - PR Newswire
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics Announces New Employee Inducement Grant PR Newswire
01.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire
19.12.25 - PR Newswire
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Smart Money Abandons Single-​Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines PR Newswire
11.12.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire
03.12.25 - PR Newswire
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-​in-Class ...
02.12.25 - PR Newswire
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial PR Newswire
01.12.25 - PR Newswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire

Newssuche

Videos

newspaper
09:50 Uhr +0,05%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »